11390 related articles for article (PubMed ID: 10647496)
1. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
[TBL] [Abstract][Full Text] [Related]
2. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Middleton MR; Kelly J; Thatcher N; Donnelly DJ; McElhinney RS; McMurry TB; McCormick JE; Margison GP
Int J Cancer; 2000 Jan; 85(2):248-52. PubMed ID: 10629085
[TBL] [Abstract][Full Text] [Related]
3. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Middleton MR; Thatcher N; McMurry TB; McElhinney RS; Donnelly DJ; Margison GP
Int J Cancer; 2002 Aug; 100(5):615-7. PubMed ID: 12124813
[TBL] [Abstract][Full Text] [Related]
4. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
5. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Lee SM; Thatcher N; Crowther D; Margison GP
Br J Cancer; 1994 Mar; 69(3):452-6. PubMed ID: 8123472
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
8. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Clemons M; Kelly J; Watson AJ; Howell A; McElhinney RS; McMurry TB; Margison GP
Br J Cancer; 2005 Nov; 93(10):1152-6. PubMed ID: 16278661
[TBL] [Abstract][Full Text] [Related]
9. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
11. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
13. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
14. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
15. Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Friedman HS; Dolan ME; Pegg AE; Marcelli S; Keir S; Catino JJ; Bigner DD; Schold SC
Cancer Res; 1995 Jul; 55(13):2853-7. PubMed ID: 7796412
[TBL] [Abstract][Full Text] [Related]
16. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Lee SM; Thatcher N; Crowther D; Margison GP
Cancer Chemother Pharmacol; 1992; 31(3):240-6. PubMed ID: 1464162
[TBL] [Abstract][Full Text] [Related]
17. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
18. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
19. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
